LLS backs 5 new can­cer drug projects with up to $50M; Trodelvy con­tin­ues to im­press with more TNBC da­ta

The Leukemia and Lym­phoma So­ci­ety has tapped 5 new ear­ly-stage projects to back with up to $10 mil­lion each in fresh in­vest­ments. The 5 biotechs are:

— Cari­bou, head­ed by Rachel Hau­r­witz and co-found­ed by Jen­nifer Doud­na, is work­ing on next-gen, off-the-shelf CAR-Ts to re­place the pa­tient-de­rived cells now in use.

— The LLS sup­port­ed Nex­Im­mune’s IPO, help­ing fund its work on nanopar­ti­cles that can gin up an im­mune re­sponse di­rect­ed at can­cer cells. The biotech has 2 projects now in Phase I tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER